A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of lGIV-C as a Corticosteroid Sparing Agent in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis
Phase of Trial: Phase II
Latest Information Update: 24 Jun 2017
At a glance
- Drugs Immune globulin (Primary)
- Indications Myasthenia gravis
- Focus Therapeutic Use
- Sponsors Grifols
- 19 Jun 2017 Planned End Date changed from 1 Dec 2017 to 1 Aug 2018.
- 19 Jun 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Jul 2018.
- 14 Oct 2016 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.